Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Heron Therapeutics, a biotechnology company, will report its first quarter 2024 financial results on May 7, 2024. The company will host a conference call and webcast to discuss recent business highlights. Investors can access the call via phone or webcast.

SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.

The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally.  Please provide the operator with the passcode 1497932 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400

View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-first-quarter-2024-financial-results-on-tuesday-may-7-2024-302126066.html

SOURCE Heron Therapeutics, Inc.

FAQ

When will Heron Therapeutics report its first quarter 2024 financial results?

Heron Therapeutics will report its first quarter 2024 financial results on May 7, 2024.

How can investors access the conference call?

Investors can access the conference call by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally and providing the operator with the passcode 1497932.

Where can the conference call be accessed via webcast?

The conference call can be accessed via webcast under the Investor Relations section of Heron's website at www.herontx.com.

For how long will the teleconference and webcast be available on Heron's website?

An archive of the teleconference and webcast will be available on Heron's website for 60 days following the call.